ORIC
ORIC Pharmaceuticals, Inc.
There isn't enough reported data to score ORIC yet.
ORIC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ORIC's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ORIC PE Valuation
ORIC has no meaningful PE right now: it lost money over the past year.
ORIC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ORIC's losses to grow, with revenue holding steady.
ORIC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.30 | +$0.60 |
| Q1 2026 | -$1.39 | +$0.49 |
| Q4 2025 | -$1.47 | +$0.36 |
| Q3 2025 | -$1.74 | +$0.06 |
| Q2 2025 | -$1.90 | -$0.15 |
| Q1 2025 | -$1.88 | -$0.08 |
| Q4 2024 | -$1.83 | +$0.13 |
| Q3 2024 | -$1.80 | +$0.19 |
ORIC is still losing money, but less than at its worst: $1.30 per share over the past year, against $2.31 at its worst in late 2022.
ORIC Quarterly Revenue
ORIC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$32M | -$1.1M |
| Q1 2026 | -$32.4M | +$480K |
| Q4 2025 | -$22.7M | +$5.6M |
| Q3 2025 | -$25.1M | +$4.1M |
| Q2 2025 | -$30.9M | -$4.9M |
| Q1 2025 | -$32.9M | -$2.5M |
| Q4 2024 | -$28.3M | -$3.9M |
| Q3 2024 | -$29.2M | -$9.5M |
ORIC has burned cash in almost every quarter: −$112M over the past year, against −$121M the year before.
ORIC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +2.5M shares |
| 1 year | +38% | +29.9M shares |
| 3 years | +140% | +62.9M shares |
| 5 years | +194% | +71.3M shares |
ORIC has 108M diluted shares, up 38% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
| Q3 2019 | — |
ORIC Net Leverage
ORIC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ORIC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.6 | Neutral |
| Stochastic | 9.0 | Oversold |
ORIC's weekly RSI is 39 (neutral) and its Stochastic is 9 (oversold).
ORIC PE vs Healthcare Sector
ORIC has no meaningful PE right now: it lost money over the past year.
ORIC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.2 | 24% below |
| 20 week MA | $11.9 | 29% below |
| 50 week MA | $10.8 | 21% below |
| 100 week MA | $10.0 | 15% below |
| 200 week MA | $9.19 | 7.5% below |
ORIC is in a downtrend: it's below all five of its weekly moving averages, and 7.5% below its 200-week average.
ORIC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.8 | $39.8 | +54% |
| 2021 | $39.8 | $16.8 | -58% |
| 2022 | $16.8 | $5.78 | -66% |
| 2023 | $5.78 | $9.20 | +59% |
| 2024 | $9.20 | $8.25 | -10% |
| 2025 | $8.25 | $8.25 | 0% |
| 2026 YTD | $8.25 | $8.50 | +3% |
ORIC has finished lower in four of the last six years. It's up 3% so far in 2026.